RxDoctor Payments Data

April Coursey, NP

Nurse Practitioner · Tyler, TXNPI 1154788941

Payments from drug & device makers

$4,706in general payments, 2019–2025

Across 124 payments — averaging $37.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Janssen Scientific Affairs, LLC$933
  • Johnson & Johnson$389
  • Madrigal Pharmaceuticals$292
  • Sanofi$211
  • Gilead$192
  • plus $820 from 13 others

What the payments were for

  • Food & beverage$4,62298%
  • Education$842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,706 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$68,258
Medicare patients
510
Services billed
991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezdiffraResmetirom44$172,645
XifaxanRifaximin56$134,299
CreonLipase/Protease/Amylase40$101,938
LinzessLinaclotide120$90,401
Mesalamine23$11,777
TrulancePlecanatide22$11,518
MovantikNaloxegol Oxalate19$10,750
Dexlansoprazole DrDexlansoprazole33$10,041
Colestipol Hcl108$9,137
Lubiprostone48$8,653
Esomeprazole Magnesium133$8,295
Pantoprazole Sodium587$7,145
Omeprazole428$6,645
Budesonide DrBudesonide23$5,218
Sucralfate113$4,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,869$192,339160 claims
Madrigal PharmaceuticalsRezdiffra$292$172,64544 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$52$145,81778 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →